HUMA
MaterialsHumacyte Inc
$0.98+0.08 (+9.03%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving HUMA Today?
No stock-specific AI insight has been generated for HUMA yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$200M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume6.1M
Avg Volume (10D)—
Shares Outstanding222.0M
HUMA News
20 articles- Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top EstimatesYahoo Finance·May 6, 2026
- Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?Yahoo Finance·May 5, 2026
- A Look At Fresenius Medical Care (XTRA:FME) Valuation After The Symvess Distribution Agreement RevisionYahoo Finance·May 3, 2026
- Fresenius Medical Care’s Symvess Deal Shift And What It Means For ValuationYahoo Finance·May 3, 2026
- Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth KnowingYahoo Finance·Apr 30, 2026
- Humacyte Highlights Dialysis Access Data; Women Show Strong ATEV Edge, V012 Results Due in JuneMarketbeat·Apr 29, 2026
- Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026Yahoo Finance·Apr 27, 2026
- Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's WhyYahoo Finance·Apr 24, 2026
- Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®Yahoo Finance·Apr 24, 2026
- Humacyte Appoints Jim Mercadante as Chief Commercial OfficerYahoo Finance·Apr 22, 2026
- Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma RepairYahoo Finance·Apr 21, 2026
- Frontier Bio Wins 'Best Paper' at 50th Annual VESS Meeting for Single-Surgery Regenerative Vascular GraftYahoo Finance·Apr 9, 2026
- Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for InvestorsYahoo Finance·Apr 7, 2026
- Why BTIG Cut Its Target on Humacyte (HUMA) but Kept a Bullish View on the Bigger OpportunityYahoo Finance·Mar 29, 2026
- Humacyte Q4 Earnings Call HighlightsMarketbeat·Mar 27, 2026
- Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 27, 2026
- Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business UpdateGlobeNewswire Inc.·Mar 27, 2026
- Humacyte Appoints Rick McElheny as Senior Vice President of Business DevelopmentYahoo Finance·Mar 26, 2026
- Is Humacyte (HUMA) Using Middle East Partnerships To Reframe Its Capital and Market Access Strategy?Yahoo Finance·Mar 24, 2026
All 20 articles loaded
Price Data
Open$0.91
Previous Close$0.90
Day High$0.99
Day Low$0.88
52 Week High—
52 Week Low—
Fundamentals
Market Cap$200M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume6.1M
Avg Volume (10D)—
Shares Outstanding222.0M
About Humacyte Inc
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—